辉瑞Elrexfio显著改善双重疗法暴露的复发或难治性多发性骨髓瘤患者的无进展生存期

美股速递
Apr 29

辉瑞公司旗下药物Elrexfio在针对复发或难治性多发性骨髓瘤患者的临床研究中取得突破性进展。该研究聚焦于已对两种主要治疗类别产生耐药性的患者群体,结果显示Elrexfio疗法能显著延长患者的无进展生存期。

这一发现为临床治疗提供了新的方向,尤其对现有疗法反应不佳的患者具有重要意义。无进展生存期是衡量肿瘤药物疗效的关键指标,其显著改善预示着该药物可能改变现有治疗格局。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10